CN1030195C - 降血糖药噻唑烷二酮及其中间体的制备方法 - Google Patents

降血糖药噻唑烷二酮及其中间体的制备方法 Download PDF

Info

Publication number
CN1030195C
CN1030195C CN92108662A CN92108662A CN1030195C CN 1030195 C CN1030195 C CN 1030195C CN 92108662 A CN92108662 A CN 92108662A CN 92108662 A CN92108662 A CN 92108662A CN 1030195 C CN1030195 C CN 1030195C
Authority
CN
China
Prior art keywords
compound
formula
hours
following formula
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN92108662A
Other languages
English (en)
Chinese (zh)
Other versions
CN1068823A (zh
Inventor
D·A·克拉克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN1068823A publication Critical patent/CN1068823A/zh
Application granted granted Critical
Publication of CN1030195C publication Critical patent/CN1030195C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN92108662A 1991-07-22 1992-07-21 降血糖药噻唑烷二酮及其中间体的制备方法 Expired - Fee Related CN1030195C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73377191A 1991-07-22 1991-07-22
US733,771 1991-07-22

Publications (2)

Publication Number Publication Date
CN1068823A CN1068823A (zh) 1993-02-10
CN1030195C true CN1030195C (zh) 1995-11-01

Family

ID=24949048

Family Applications (1)

Application Number Title Priority Date Filing Date
CN92108662A Expired - Fee Related CN1030195C (zh) 1991-07-22 1992-07-21 降血糖药噻唑烷二酮及其中间体的制备方法

Country Status (19)

Country Link
US (1) US6329408B1 (https=)
EP (1) EP0641338A1 (https=)
JP (1) JPH08823B2 (https=)
CN (1) CN1030195C (https=)
AU (1) AU665775B2 (https=)
BR (1) BR9206293A (https=)
CA (1) CA2111447C (https=)
CZ (1) CZ282831B6 (https=)
HU (1) HUT69692A (https=)
IE (1) IE922357A1 (https=)
IL (1) IL102573A (https=)
MX (1) MX9204279A (https=)
NO (1) NO301226B1 (https=)
NZ (1) NZ243653A (https=)
PT (1) PT100711B (https=)
RU (1) RU2079497C1 (https=)
TW (1) TW222626B (https=)
WO (1) WO1993002079A1 (https=)
ZA (1) ZA925468B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0595868B1 (en) * 1991-07-22 1998-11-25 Pfizer Inc. Process for the preparation of (s)-4-[3-(5-methyl-2-phenyl-4-oxazolyl)- 1-hydroxypropyl]bromobenzene
GB9308487D0 (en) * 1993-04-23 1993-06-09 Smithkline Beecham Plc Novel compounds
BR9810142A (pt) 1997-06-18 2000-08-08 Smithkline Beecham Plc Tratamento de diabete com tiazolidinadiona e sulfonil-uréia
AR023699A1 (es) 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
CZ20011629A3 (cs) * 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
YU72201A (sh) * 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
TWI302149B (en) * 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
IL149493A0 (en) * 1999-11-10 2002-11-10 Takeda Chemical Industries Ltd 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
AU5884101A (en) * 2000-05-26 2001-12-03 Nippon Shinyaku Co Ltd Heterocyclic compounds
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
JP2003040877A (ja) * 2001-07-24 2003-02-13 Sumika Fine Chemicals Co Ltd ５−［６−（２−フルオロベンジルオキシ）−２−ナフチル］メチル−２，４−チアゾリジンジオンの製造方法及びその精製方法
ATE422884T1 (de) * 2002-06-03 2009-03-15 Novartis Pharma Gmbh Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
BR0312452A (pt) * 2002-07-03 2005-04-19 Hoffmann La Roche Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; e método para o tratamento e/ou profilaxia de doenças que são moduladas por agonistas de ppar(alfa) e/ou ppar(gama)
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
MXPA06003205A (es) * 2003-09-22 2006-06-23 Ono Pharmaceutical Co Derivados de acido fenilacetico, proceso para producir el mismo y uso.
DE602004004631D1 (de) * 2004-04-01 2007-03-22 Sanofi Aventis Deutschland Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
WO2016071727A1 (en) 2014-11-04 2016-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
CN109867765A (zh) * 2019-02-28 2019-06-11 中山大学惠州研究院 一种长效缓释可降解防污聚氨酯及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4342771A (en) 1981-01-02 1982-08-03 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4367234A (en) 1980-07-28 1983-01-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4617312A (en) 1983-01-17 1986-10-14 Pfizer Inc. Aldose reductase inhibiting 5-(2-alkoxyphenyl) thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
HU210339B (en) 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
GB8713861D0 (en) * 1987-06-13 1987-07-15 Beecham Group Plc Compounds
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
US5036079A (en) 1989-12-07 1991-07-30 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents

Also Published As

Publication number Publication date
AU2297392A (en) 1993-02-23
RU2079497C1 (ru) 1997-05-20
CZ12494A3 (en) 1994-07-13
CZ282831B6 (cs) 1997-10-15
HU9400181D0 (en) 1994-05-30
US6329408B1 (en) 2001-12-11
IL102573A (en) 1997-04-15
JPH08823B2 (ja) 1996-01-10
BR9206293A (pt) 1994-11-08
AU665775B2 (en) 1996-01-18
NO940225L (no) 1994-01-21
PT100711B (pt) 1999-07-30
MX9204279A (es) 1994-03-31
IL102573A0 (en) 1993-01-14
ZA925468B (en) 1994-01-21
HUT69692A (en) 1995-09-28
TW222626B (https=) 1994-04-21
CA2111447A1 (en) 1993-02-04
NO940225D0 (no) 1994-01-21
CN1068823A (zh) 1993-02-10
NO301226B1 (no) 1997-09-29
CA2111447C (en) 2002-08-13
IE922357A1 (en) 1993-01-27
JPH07502487A (ja) 1995-03-16
PT100711A (pt) 1993-09-30
WO1993002079A1 (en) 1993-02-04
EP0641338A1 (en) 1995-03-08
NZ243653A (en) 1995-02-24

Similar Documents

Publication Publication Date Title
CN1030195C (zh) 降血糖药噻唑烷二酮及其中间体的制备方法
US5089514A (en) 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
CA2029703C (en) Oxazolidinedione hypoglycemic agents
CN1069901C (zh) N－苄基二氧代噻唑烷基苯甲酰胺衍生物及其制造方法
IE890738L (en) Hypoglycemic thiazolidinedione derivatives
CN88101542A (zh) 新颖的苯并唑衍生物及其制备方法
CN1069023A (zh) 用于治疗肥胖及相关状态的4-[2-(2-羟基-2-苯乙氨基)乙氧基]苯乙酸衍生物
CN1321152A (zh) 作为hPPARγ和hPPARα激活剂的取代的噁唑和噻唑衍生物
JPH0465075B2 (https=)
EP0389699B1 (en) Thiazolidinedione derivatives as hypoglycemic agents
US5498621A (en) Oxazolidinedione hypoglycemic agents
CN1221410A (zh) 新型取代的2,4－噻唑烷二酮衍生物,其制备方法以及含有它们的药物组合物
US4968707A (en) Oxazolidin-2-one derivatives as hypoglycemic agents
CN1044705C (zh) (1-苯基-1-杂环基)烷烃衍生物、它们的制备方法及其用途
CN1069022A (zh) 用于治疗肥胖及相关状态的4-[2-(2-羟基-2-苯乙氨基)乙氧基]苯乙酸衍生物
EP0591252B1 (en) Thiazolidinedione hypoglycemic agents
CN1065269A (zh) 哒嗪酮乙酸衍生物
WO1991003474A1 (en) Hypoglycemic thiazolidinedione derivatives
IE63187B1 (en) Thiazolidinedione derivatives as hypoglycemic agents

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee